Plain-English translation of NCT07192900 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called Fast TILs, which uses your own immune cells to fight cancer that has spread to the tissue lining your lungs (called the pleura). Doctors will collect fluid from around your lungs, grow special immune cells in the lab, and then put those cells back into the pleural space along with a medication called (IL-2) to help boost their cancer-fighting power.
Cancers that spread to the lung lining often stop responding to standard treatments, leaving patients with limited options. This trial exists to test whether using a patient's own immune system—specifically cells already present in the pleural fluid—might be a new way to control this type of advanced cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will first place a small catheter (tube) in the space around your lungs to drain fluid. They will use that fluid to grow your immune cells in the laboratory over several weeks. Once the cells are ready, you will receive a single infusion of these cells through the same catheter, followed by four doses of (a protein that activates immune cells) given over a few days. The research team will monitor you closely and collect additional fluid samples before and after treatment to understand how the medication is working.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States